Abstract
The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 425-433 |
| Number of pages | 9 |
| Journal | Journal of Endocrinology |
| Volume | 158 |
| Issue number | 3 |
| Publication status | Published - Sep 1998 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
Cite this
Epidermal growth factor binding sites in human pituitary macroadenomas. / Jaffrain-Rea, M. L.; Petrangeli, E.; Lubrano, C.; Minniti, G.; Di Stefano, D.; Sciarra, F.; Frati, L.; Tamburrano, G.; Cantore, G.; Gulino, A.
In: Journal of Endocrinology, Vol. 158, No. 3, 09.1998, p. 425-433.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Epidermal growth factor binding sites in human pituitary macroadenomas
AU - Jaffrain-Rea, M. L.
AU - Petrangeli, E.
AU - Lubrano, C.
AU - Minniti, G.
AU - Di Stefano, D.
AU - Sciarra, F.
AU - Frati, L.
AU - Tamburrano, G.
AU - Cantore, G.
AU - Gulino, A.
PY - 1998/9
Y1 - 1998/9
N2 - The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.
AB - The number of epidermal growth factor (EGF) binding sites was determined by competitive binding assays in a series of 46 pituitary macroadenomas. A single concentration of 125I-EGF (1 nM) was used for all experiments. In four cases, a displacement curve was obtained by adding increasing concentrations of cold EGF, and Scatchard analysis showed the presence of two classes of EGF binding sites, with K(d1)=0.62 ± 0.23 nM and K(d2)=53.8 ± 8.2 nM for the high- and low-affinity binding sites respectively. The distribution of EGF binding sites was studied in 42 cases by a single-point assay, in the presence and in the absence of a 100-fold cold EGF excess. A non-parametric distribution of EGF binding sites was observed (median 10.2 fmol/mg membrane protein, range 0.0-332.0). EGF-receptor positivity, defined as EGF binding ≤10.0 fmol/mg protein, was observed in 23 samples (54.8%), especially in prolactinomas (76.5%, P3H]methyltrienolone. No correlation could be found between EGF binding and either the gender and gonadal status of the patients, or the expression of SSRs by the adenomas. We conclude that the EGF family of growth factors may play a role in the evolution of a significant subset of human pituitary adenomas, especially in their invasiveness, and that a high EGF binding capacity may represent an additional marker of aggressiveness for these tumors. Sex steroids do not appear to have a significant role in the regulation of EGF binding in vivo in these tumors.
UR - http://www.scopus.com/inward/record.url?scp=0031708554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031708554&partnerID=8YFLogxK
M3 - Article
C2 - 9846172
AN - SCOPUS:0031708554
VL - 158
SP - 425
EP - 433
JO - Journal of Endocrinology
JF - Journal of Endocrinology
SN - 0022-0795
IS - 3
ER -